This article is more than 5 years old. Information may no longer be current.
NanoViricides, St. Jude Children’s partner to explore anti-flu drug candidates
Click Here to Manage Email Alerts
NanoViricides is collaborating with St. Jude Children’s Research Hospital to further advance the company’s anti-influenza program, according to a press release.
After receiving FDA guidance, NanoViricides has been investigating its anti-influenza drug candidate FluCide-1 in chemistry, manufacture and control studies and scaled-up production for the drug. The company plans to develop additional drug candidates superior to FluCide-1, the release said.
Elena A. Govorkova, MD, PhD, and Robert G. Webster, PhD, of St. Jude’s department of infectious diseases, will lead the testing of both injectable and oral drug candidates. The researchers have “extensive experience” with influenza viruses and antiviral agents, according to the release. They will evaluate the efficacy and potency of the antiviral agents against influenza A and B viruses on a number of cell types, including human bronchial epithelial cells.
Disclosure: Infectious Disease News was unable to confirm relevant financial disclosures at the time of publication.